Immunologic evidence for lack of heterologous protection following resolution of HCV in patients with non-genotype 1 infection

Blood

Volumn 110, Issue 5, 2007, Pages 1559-1569

  Zur Wiesch, Julian Schulze ^a,b,c,d   Lauer, Georg M ^a   Timm, Joerg ^e   Kuntzen, Thomas ^a   Neukamm, Martin ^a   Berical, Andrew ^a   Jones, Andrea M ^a   Nolan, Brian E ^a   Longworth, Steve A ^a   Kasprowicz, Victoria ^a   McMahon, Cory ^a   Wurcel, Alysse ^a   Lohse, Ansgar W ^c   Lewis Ximenez, Lia L ^f   Chung, Raymond T ^a   Kim, Arthur Y ^a   Allen, Todd M ^a   Walker, Bruce D ^a,b,g  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d LEIBNIZ INSTITUTE FOR EXPERIMENTAL VIROLOGY   (Germany)

^e UNIVERSITY HOSPITAL ESSEN   (Germany)

^f INSTITUTO OSWALDO CRUZ   (Brazil)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT PROTEIN; VIRUS PROTEIN;

ADULT; AGED; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FLOW CYTOMETRY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNE RESPONSE; LYMPHOCYTE PROLIFERATION; MALE; PRIORITY JOURNAL; SEROTYPING; VIREMIA; VIRUS INFECTION; VIRUS TRANSMISSION;

EID: 34548844159     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-01-069583     Document Type: Article

References (63)

1. Gerlach JT, Diepolder HM, Zachoval R, et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology. 2003;125:80-88.
2. Mehta SH, Cox A, Hoover DR, et al. Protection against persistence of hepatitis C. Lancet. 2002;359:1478-1483.
3. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol. 2005;5:215-229.
4. Grebely J, Conway B, Raffa JD, Lai C, Krajden M, Tyndall MW. Hepatitis C virus reinfection in injection drug users. Hepatology. 2006;44:1139-1145.
5. Corey KE, Ross AS, Wurcel A, et al. Outcomes and Treatment of Acute Hepatitis C Virus Infection in a United States Population. Clin Gastroenterol Hepatol. 2006;4:1278-1282.
6. Diepolder HM, Zachoval R, Hoffmann RM, et al. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet. 1995;346:1006-1007.
7. Lechner F, Wong DK, Dunbar PR, et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med. 2000;191:1499-1512.
8. Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, Chisari FV. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med. 2001;194:1395-1406.
9. Chang KM, Thimme R, Melpolder JJ, et al. Differential CD4(+) and CD8(+) T-cell responsiveness in hepatitis C virus infection. Hepatology. 2001;33:267-276.
10. Schulze zur Wiesch J, Lauer GM, Day CL et al. Broad repertoire of the CD4+ Th cell response in spontaneously controlled hepatitis C virus infection includes dominant and highly promiscuous epitopes. J Immunol. 2005;175:3603-3613.
11. Day CL, Lauer GM, Robbins GK, et al. Broad specificity of virus-specific CD4+ T-helper-cell responses in resolved hepatitis C virus infection. J Virol. 2002;76:12584-12595.
12. Bowen DGC, Walker M. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature. 2005;436:946-952.
13. Chisari FV. Unscrambling hepatitis C virus-host interactions. Nature. 2005;436:930-932.
14. Shoukry NH, Cawthon AG, Walker CM. Cell-mediated immunity and the outcome of hepatitis C virus infection. Annu Rev Microbiol. 2004;58:391-424.
15. Hahn YS. Subversion of immune responses by hepatitis C virus: immunomodulatory strategies beyond evasion? Curr Opin Immunol. 2003;15:443-449.
16. Simmonds P. Genetic diversity and evolution of hepatitis C virus-15 years on. J Gen Virol. 2004;85:3173-3188.
17. Houghton M, Abrignani S. Prospects for a vaccine against the hepatitis C virus. Nature. 2005;436:961-966.
18. Kao JH, Chen PJ, Lai MY, Chen DS. Superinfection of heterologous hepatitis C virus in a patient with chronic type C hepatitis. Gastroenterology. 1993;105:583-587.
19. Kao JH, Chen PJ, Wang JT, et al. Superinfection by homotypic virus in hepatitis C virus carriers: studies on patients with post-transfusion hepatitis. J Med Virol. 1996;50:303-308.
20. Lai ME, Mazzoleni AP, Argiolu F, et al. Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassaemic children. Lancet. 1994;343:388-390.
21. Proust B, Dubois F, Bacq Y, et al. Two successive hepatitis C virus infections in an intravenous drug user. J Clin Microbiol. 2000;38:3125-3127.
22. Lanford RE, Guerra B, Chavez D, et al. Crossgenotype immunity to hepatitis C virus. J Virol. 2004;78:1575-1581.
23. Prince AM, Brotman B, Lee DH, et al. Protection against chronic hepatitis C virus infection after rechallenge with homologous, but not heterologous, genotypes in a chimpanzee model. J Infect Dis. 2005;192:1701-1709.
24. Shoukry NH, Sidney J, Sette A, Walker CM. Conserved hierarchy of helper T cell responses in a chimpanzee during primary and secondary hepatitis C virus infections. J Immunol. 2004;172:483-492.
25. Okamoto H, Mishiro S, Tokita H, Tsuda F, Miyakawa Y, Mayumi M. Superinfection of chimpanzees carrying hepatitis C virus of genotype II/1b with that of genotype III/2a or I/1a. Hepatology. 1994;20:1131-1136.
26. Folgori A, Capone S, Ruggeri L, et al. A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat Med. 2006;12:190-197.
27. Hultgren C, Desombere I, Leroux-Roels G, et al. Evidence for a relation between the viral load and genotype and hepatitis C virus-specific T cell responses. J Hepatol. 2004;40:971-978.
28. Kaplan DE, Sugimoto K, Ikeda F, et al. T-cell response relative to genotype and ethnicity during antiviral therapy for chronic hepatitis C. Hepatology. 2005;41:1365-1375.
29. Diepolder HM. Interferon-alpha for hepatitis C: antiviral or immunotherapy? J Hepatol. 2004;40:1030-1031.
30. Zein NN. Clinical significance of hepatitis C virus genotypes. Clin Microbiol Rev. 2000;13:223-235.
31. Harcourt GC, Lucas M, Godkin AJ, Kantzanou M, Phillips RE, Klenerman P. Evidence for lack of cross-genotype protection of CD4+ T cell responses during chronic hepatitis C virus infection. Clin Exp Immunol. 2003;131:122-129.
32. Sugimoto K, Kaplan DE, Ikeda F, et al. Strainspecific T-cell suppression and protective immunity in patients with chronic hepatitis C virus infection. J Virol. 2005;79:6976-6983.
33. Toyoda H, Fukuda Y, Hayakawa T, et al. Presence of multiple genotype-specific antibodies in patients with persistent infection with hepatitis C virus (HCV) of a single genotype: evidence for transient or occult superinfection with HCV of different genotypes. Am J Gastroenterol. 1999;94:2230-2236.
34. Kuiken C, Yusim K, Boykin L, Richardson R. The Los Alamos hepatitis C sequence database. Bioinformatics. 2005;21:379-384.
35. European Union. European HCV Database. http://euhcvdb.ibcp.fr/euHCVdb/. Accessed January 2, 2006.
36. National Institute of Allergies and Infectious Diseases. HCV Virus Database Project. http://hcv-.lanl.gov/content/hcv-db/index. Accessed January 2, 2006.
37. Timm J, Lauer GM, Kavanagh DG, et al. CD8 epitope escape and reversion in acute HCV infection. J Exp Med. 2004;200:1593-1604.
38. Bunce M, Fanning GC, Welsh KI. Comprehensive, serologically equivalent DNA typing for HLA-B by PCR using sequence-specific primers (PCR-SSP). Tissue Antigens. 1995;45:81-90.
39. Bunce M, O'Neill CM, Barnardo MC, et al. Phototyping: comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5 and DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP). Tissue Antigens. 1995;46:355-367.
40. Lauer GM, Lucas M, Timm J, et al. Full-breadth analysis of CD8+ T-cell responses in acute hepatitis C virus infection and early therapy. J Virol. 2005;79:12979-12988.
41. Gerlach JT, Ulsenheimer A, Gruner NH, et al. Minimal T-cell-stimulatory sequences and spectrum of HLA restriction of immunodominant CD4+ T-cell epitopes within hepatitis C virus NS3 and NS4 proteins. J Virol. 2005;79:12425-12433.
42. Diepolder HM, Gerlach JT, Zachoval R, et al. Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection. J Virol. 1997;71:6011-6019.
43. Lamonaca V, Missale G, Urbani S, et al. Conserved hepatitis C virus sequences are highly immunogenic for CD4(+) T cells: implications for vaccine development. Hepatology. 1999;30:1088-1098.
44. Timm J, Lauer GM, Kavanagh DG, et al. CD8 epitope escape and reversion in acute HCV infection. J Exp Med. 2004;200:1593-1604.
45. Battegay M, Moskophidis D, Rahemtulla A, Hengartner H, Mak TW, Zinkernagel RM. Enhanced establishment of a virus carrier state in adult CD4+ T-cell-deficient mice. J Virol. 1994;68:4700-4704.
46. Day CLB, Walker D. Progress in defining CD4 helper cell responses in chronic viral infections. J Exp Med. 2003;198:1773-1777.
47. Janssen EM, Lemmens EE, Wolfe T, Christen U, von Herrath MG, Schoenberger SP. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature. 2003;421:852-856.
48. Planz O, Ehl S Furrer E, et al. A critical role for neutralizing- antibody-producing B cells, CD4(+) T cells, and interferons in persistent and acute infections of mice with lymphocytic choriomeningitis virus: implications for adoptive immunotherapy of virus carriers. Proc Natl Acad Sci U S A. 1997;94:6874-6879.
49. Shedlock DJ, Shen H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science. 2003;300:337-339.
50. Shedlock DJ, Whitmire JK, Tan J, MacDonald AS, Ahmed R, Shen H. Role of CD4 T cell help and costimulation in CD8 T cell responses during Listeria monocytogenes infection. J Immunol. 2003;170:2053-2063.
51. Sun JCM, Bevan J. Defective CD8 T cell memory following acute infection without CD4 T cell help. Science. 2003;300:339-342.
52. von Herrath MG, Yokoyama M, Dockter J, Oldstone MB, Whitton JL. CD4-deficient mice have reduced levels of memory cytotoxic T lymphocytes after immunization and show diminished resistance to subsequent virus challenge. J Virol. 1996;70:1072-1079.
53. Kaech SM, Ahmed R. Immunology: CD8 T cells remember with a little help. Science. 2003;300:263-265.
54. Diepolder HM, Jung MC, Keller E, et al. A vigorous virus-specific CD4+ T cell response may contribute to the association of HLA-DR13 with viral clearance in hepatitis B. Clin Exp Immunol. 1998;113:244-251.
55. Folgori A, Spada E, Pezzanera M, et al. Early impairment of HCV-specific T-cell proliferation during acute infection leads to failure of viral clearance. Gut. 2006;55:1012-1019.
56. Gerlach JT, Diepolder HM, Jung MC, et al. Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C. Gastroenterology. 1999;117:933-941.
57. Ulsenheimer A, Gerlach JT, Gruener NH, et al. Detection of functionally altered hepatitis C virus-specific CD4 T cells in acute and chronic hepatitis C. Hepatology. 2003;37:1189-1198.
58. Rehermann BE, Shin C. Private aspects of heterologous immunity. J Exp Med. 2005;201:667-670.
59. Mongkolsapaya J, Dejnirattisai W, Xu XN, et al. Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat Med. 2003;9:921-927.
60. Mangada MMA, Rothman L. Altered cytokine responses of dengue-specific CD4+ T cells to heterologous serotypes. J Immunol. 2005;175:2676-2683.
61. Rothman AL. Dengue: defining protective versus pathologic immunity. J Clin Invest. 2004;113:946-951.
62. Yee LJ. Host genetic determinants in hepatitis C virus infection. Genes Immun. 2004;5:237-245.
63. Smyk-Pearson S, Tester IA, Lezotte D, Sasaki AW, Lewinsohn DM, Rosen HR. Differential antigenic hierarchy associated with spontaneous recovery from hepatitis C virus infection: implications for vaccine design. J Infect Dis. 2006;194:454-463.